HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

511.821

-20.567-3.86%

Number of Gainers:2

Number of Losers:28

Number of Flat:3

PE:- -

High:526.804

Open:526.804

Low:504.120

Close:532.388

Volume:24.72M

Turnover:643.27M

Market Cap:323.73B

Float Cap:289.78B

Loading ...

Hong Kong Stocks Slip as Property and Biotech ETF Sectors Rally on Policy Signals

AH Premium Statistics for September 29

China Innovation Drug ETF (03525) Rises Over 2%, Focusing on R&D-Driven Quality Innovative Drug Companies in Hong Kong and Developed Markets

CStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth

Keymed Bio-B Jumps Over 9% in Afternoon Trading, Company Holds Strong Competitive Edge Across Multiple Innovative Drug Areas Including Autoimmune and Oncology

Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live

GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation

InnoCare Pharma Jumps Over 5% Intraday After Signing R&D Collaboration and License Agreement with Eli Lilly

China A-Share Indices Reverse Early Gains as Real Estate Stocks Surge, Vanke Hits Limit Up, Biotech Rallies, Hang Seng Tech Falls Over 1%, New Energy Vehicle Shares Decline

Hong Kong Stocks Open: Hang Seng Index Turns Lower After Flat Start; Pharma Shares Defy Trend as AKESO Surges Nearly 10%

Estimating the Value of PL-5: How Much Is This Wound Infection Candidate Worth for HK-Listed Aspirant Prolytix?

Prairie Pharmaceutical's Second Attempt at HKEX Listing: Cash Crunch, Billion-Yuan Redemption Liability Looming, Core Product Commercialization Faces Multiple Hurdles

Akeso Biotech Jumps Over 8% at Open as AstraZeneca Makes US$2 Billion Strategic Investment in Summit, Ivonescimab Gains Backing from Top Pharma

Eli Lilly Has Already Spent Over $20 Billion This Year! CEO Says It Will Target Pharma "White Spaces" and Continue Pursuing Larger Acquisitions

AstraZeneca's $2 Billion Stake in Summit Signals Confidence in Akeso's Ivonescimab

CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B

CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":511.8213,"timestamp":1790920094403,"preClose":532.3884,"halted":0,"volume":24721039,"delay":0,"changeRate":-0.038632,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-20.567139,"latestTime":"10-02 13:48:14","open":526.80365,"high":526.80365,"low":504.12042,"amount":643265029,"amplitude":0.042607,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790928600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"pbRate":3.967371,"peRate":176.437057,"turnoverRate":0.000941,"increases":2,"decrements":28,"flats":2,"marketCap":323727489184,"floatMarketCap":289783063016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":526.80365,"amplitude":0.042607,"preClose":532.3884,"low":504.12042,"pbRate":"3.967371","latestPrice":511.8213,"volume":24721039,"delay":0,"open":526.80365,"prevYearClose":556.26263,"prevWeekClose":495.27,"prevMonthClose":532.388,"prevQuarterClose":532.388,"fiveDayClose":495.278,"twentyDayClose":515.473,"sixtyDayClose":490.453,"secType":"PLATE","market":"HK","turnoverRate":0.000941,"peRate":176.437057,"marketCap":323727489184,"floatMarketCap":289783063016,"timestamp":1790920094403,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":2,"down":28,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113675289","title":"Hong Kong Stocks Slip as Property and Biotech ETF Sectors Rally on Policy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=1113675289","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113675289?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:43","pubTimestamp":1790671392,"startTime":"0","endTime":"0","summary":"Hong Kong's three major indices closed slightly lower today, with heavyweight technology stocks weakening and structural divergence across the board standing out, while mainland property and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","FDN","BK1161","06978","LNGR","MEDX","IBBQ","159992","BK4585","BK4550","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140639624","title":"AH Premium Statistics for September 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1140639624","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140639624?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:21","pubTimestamp":1790670095,"startTime":"0","endTime":"0","summary":"As of the market close on September 29, NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) ranked as the top three stocks by AH premium rate, with premium rates of 1155.81%,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","BK1116","01108","LU0593848301.USD","LU0918141705.HKD","LU0072913022.USD","IE00BZ08YS42.EUR","02218","02846","IE00BMCWC346.EUR","IE0008368742.USD","LU0067412154.USD","00991","IE00BGHQDM52.EUR","LU0797268264.HKD","BK1546","LU0149721374.USD","BK1507","BK1190","03328","01057","LU0052750758.USD","IE00B543WZ88.USD","LU2226246903.HKD","LU2097828805.USD","LU0516422440.USD","LU2097828714.EUR","HK0000352382.USD","BK1521","IE00BZ08YR35.GBP","LU0823426308.USD","BK1515","LU0431992006.USD","LU0672654166.SGD","BK1125","BK1141","BK1539","00568","BK1530","01033","LU0348805143.USD","LU1224709979.USD","LU1211504680.USD","IE0034224299.USD","LU0320764599.SGD","LU0048580855.USD","LU2097828557.USD","HK0001040168.HKD","LU0327786744.USD","LU0823426480.USD","BK1144","LU2097828474.EUR","LU0329678337.USD","LU0417516902.SGD","LU1282649141.HKD","00811","LU1960683339.HKD","LU1366334578.USD","02338","IE0008369823.USD","LU0417516738.SGD","BK1522","LU0106959298.USD","LU0648948544.HKD","LU2476274308.USD","BK1122","LU2294711473.HKD","06951","BK1237","LU0348814723.USD","LU0348788117.USD","BK1544","03200","LU0531970944.HKD","LU0821914370.USD","LU0307460666.USD","BK1191","BK1554","LU0128522157.USD","LU0329678170.USD","LU1675838814.USD","LU1115378108.SGD","BK1183","LU0828237510.HKD","LU0228659784.USD","IE00B031HY20.USD","BK1562","SG9999011746.SGD","02359","BK1583","LU0049853897.USD","BK1202","LU0348825331.USD","BK1193","03968","HK0000306701.USD","BK1170","LU0456827905.SGD","83188","LU1255011170.USD","LU1282649067.USD","LU0082770016.SGD","LU0266512127.USD","01812","SG9999001226.SGD","06185","LU1282648689.USD","LU0516423174.USD","82843","LU0561508036.HKD","LU0516422366.SGD","LU1481107354.HKD","02899","LU1366334651.USD","LU1282649810.SGD","82846","HK0000306685.HKD","LU0039217434.USD","LU1504937902.USD","LU0117841782.USD","LU0455707207.USD","LU0463099449.HKD","159982","LU3063872942.SGD","06127","IE00B3M56506.USD","HK0001040143.USD","LU1303224171.USD","LU1988902786.USD","LU0886674414.USD","LU2242644610.SGD","03986","LU0061477393.USD","LU1048596156.SGD","BK1223","SG9999006597.SGD","LU0708995583.HKD","LU0181495838.USD","LU1831875114.USD","LU0043850808.USD","BK1249","LU0214875030.USD","LU1807302812.USD","LU2097828631.EUR","LU0348816934.USD","BK1171","LU0918141887.USD","LU0328353924.USD","02238","LU2045819591.USD","LU0320764755.SGD","LU1244550577.SGD","SG9999004220.SGD","LU0634319403.HKD","BK1119","00042","03750","LU0228367735.SGD","SG9999002463.SGD","02691","LU2177674079.SGD","LU0140636845.USD","07233","LU0266512473.USD","LU0589944569.HKD","02865","BK1594","LU0384037296.USD","LU1152091754.HKD","LU0229945570.USD","BK1147","LU0345780521.USD","LU0348735423.USD","LU1769817179.HKD","IE00BF5LJ272.USD","LU0531971595.HKD","BK1533","LU0359201885.HKD","LU0348766576.USD","LU0449509016.USD","LU1064131342.USD","LU0051755006.USD","03308","LU0173614495.USD","LU2039709279.SGD","LU0359201612.USD","03143","LU0149534421.HKD","LU0588546209.SGD","02827","09976","03188","00553","LU1244550221.USD","LU1688375341.USD","IE00B031J352.USD","LU0572944931.SGD","LU2778985437.USD","LU0359202008.SGD","LU0348767384.USD","LU1328277881.USD","LU1023057109.AUD","LU0326950275.SGD","LU0502904849.HKD","LU0029875118.USD","LU0287142896.SGD","BK1149","LU1251922891.USD","BK1198","EWH","HK0000352291.HKD","82823","LU1961090484.USD","LU0890818403.SGD","LU1655091616.SGD","IE0032431581.USD","BK1231","LU1880383440.USD","LU0607220059.USD","LU0543330566.HKD","BK1574","02823","02822","LU1188198961.HKD","LU1242518857.USD","LU0868486357.SGD","LU1226287529.USD","LU0211977185.USD","06067","BK1163","LU0231483743.USD","LU0862451753.SGD","02843","LU1046422090.SGD","LU0164939612.USD","LU0314109678.HKD","LU0082770016.USD","BK1560","BK1181","LU0516423091.SGD","SG9999002828.SGD","LU0164880469.USD","LU2476274720.SGD","02701","LU0540923850.HKD","LU0979878070.USD","IE00BZ08YT58.USD","LU1770034418.SGD","LU0488056044.USD","06821","BK1505","LU0164865239.USD","LU2264538146.SGD","BK1105","BK1130","LU1206782309.USD","LU0737861699.HKD","BK1514","LU1008478684.HKD","LU0106252389.USD","IE00B5MMRT66.SGD","03996","LU0345780281.USD","LU0791590937.USD","LU0163747925.USD","LU0501845795.SGD","BK1551","LU1880383366.USD","LU0269904917.USD","LU0871576103.HKD","82822","LU0348827113.USD","01349","HK0000320223.HKD","IE00BYV24P56.USD","LU0456854461.SGD","LU1242518931.SGD","BK1110","IE00BVYPNQ40.USD","03228","LU1993786604.SGD","LU0828238088.HKD","LU0509642566.USD","LU2008162690.USD","83130","BK1576","03130","LU1794554557.SGD","LU2399975544.HKD","LU0737861772.HKD","LU1152091168.USD","LU0254981946.USD","SG9999014674.SGD","03678","LU2125910500.SGD","LU1719994722.HKD","BK1592","LU0543330483.HKD","LU1105468828.SGD","IE0031814852.USD","LU0469268626.HKD","LU0828237940.HKD","LU0315179316.USD","IE00BVYPNP33.GBP","LU0516422952.EUR","LU1813983027.USD","LU0370786039.SGD","BK1161","LU0244354667.USD","399300","LU1808992512.USD","00187","LU1769817096.USD","02475","SG9999001093.SGD","LU0165289439.USD","LU0880133367.SGD","LU0456846285.SGD","LU0640798160.USD","BK1564","LU0791591158.USD","LU0096374516.USD","LU1244550494.USD","LU1720050803.USD","HK0000320264.USD","LU0210526637.USD","LU0620787316.HKD","BK1148","IE00B29SXG58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113085280","title":"China Innovation Drug ETF (03525) Rises Over 2%, Focusing on R&D-Driven Quality Innovative Drug Companies in Hong Kong and Developed Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1113085280","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113085280?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:22","pubTimestamp":1790666534,"startTime":"0","endTime":"0","summary":"According to Zhitong Finance APP, China Innovation Drug ETF (03525) rose over 2%, reaching 2% as of press time, at HK$10.2, with a turnover of HK$491,300.It is reported that the China Innovation Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","03525","BK4550","IBBQ","BK4588","MEDX","BK4585","159992","WSGE","FDN","BK1161","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172233611","title":"CStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1172233611","media":"Stock News","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172233611?lang=en_us&edition=fundamental","pubTime":"2026-09-29 14:10","pubTimestamp":1790662217,"startTime":"0","endTime":"0","summary":"According to Zhitong Finance APP, CStone Pharma-B (HKEX: 02616) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.On the news front, the latest clinical data...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","KCAI","VXUS","BK4585","BK4588","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110569578","title":"Keymed Bio-B Jumps Over 9% in Afternoon Trading, Company Holds Strong Competitive Edge Across Multiple Innovative Drug Areas Including Autoimmune and Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1110569578","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110569578?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:50","pubTimestamp":1790661039,"startTime":"0","endTime":"0","summary":"Keymed Bio-B (02162) rose more than 8% in afternoon trading, climbing 8.95% as of press time to HKD 79.70, with a turnover of HKD 237 million.Earlier this month, Keymed Bio-B (02162) announced that...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1587","BK1161","02162","IBBQ","BK1583","MEDX","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293640","title":"Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293640","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671293640?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:39","pubTimestamp":1790660392,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.The treatment was safe and well tolerated, with all adverse events reported as mild and transient.Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156162380","title":"GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1156162380","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156162380?lang=en_us&edition=fundamental","pubTime":"2026-09-29 11:31","pubTimestamp":1790652676,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.On the news front, the company's self-developed oral...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","VXUS","BK4588","159938","02595","KCAI","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152948849","title":"InnoCare Pharma Jumps Over 5% Intraday After Signing R&D Collaboration and License Agreement with Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=1152948849","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152948849?lang=en_us&edition=fundamental","pubTime":"2026-09-29 11:00","pubTimestamp":1790650823,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (09969) saw its intraday gain exceed 5%. As of press time, the stock was up 2.62% at HK$14.47, with a turnover of HK$42.1518 million.InnoCare Pharma recently announced that it has...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688428","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183825958","title":"China A-Share Indices Reverse Early Gains as Real Estate Stocks Surge, Vanke Hits Limit Up, Biotech Rallies, Hang Seng Tech Falls Over 1%, New Energy Vehicle Shares Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1183825958","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183825958?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:34","pubTimestamp":1790649241,"startTime":"0","endTime":"0","summary":"On September 29, A-share markets traded lower in morning session, with the three major indices collectively reversing early gains after an initial rally. The micro-cap stock index rebounded, the real...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02202","LU0348827113.USD","LU0072913022.USD","LU0708995583.HKD","EVS.SI","BK0278","LU1993786604.SGD","NIO.SI","BK0201","LU2399975544.HKD","BK4504","03417","BK1574","BK4548","07552","03067","IE00B5MMRT66.SGD","BK4534","LU1961090484.USD","IE00B543WZ88.USD","LU0320764599.SGD","BK0183","LU0348735423.USD","LU1655091616.SGD","LU1226287529.USD","000002","LU0561508036.HKD","LU0348783233.USD","IE00B0JY6N72.USD","BK4532","LU0348825331.USD","03032","HSTECH","LU1720050803.USD","03033","BK0188","BK1161","BK0028","LU2476274720.SGD","09866","LU2778985437.USD","BK4526","LU2148510915.USD","BK0086","BK4505","BK0157","LU0348767384.USD","BK4588","BK0196","LU1580142542.USD","LU0501845795.SGD","BK0180","HSI","LU0348784397.USD","BK4531","LU2476274308.USD","03088","LU0067412154.USD","LU1064131003.USD","07226","LU1328615791.USD","IE00BPRC5H50.USD","HTImain","BK0273","LU0052750758.USD","000001","02837","09088","03423","BK4585","LU0417516571.SGD","LU1781817850.SGD","NIO","LU0417516902.SGD","LU0634319403.HKD","BK0178","LU1807302812.USD","BK4581","LU0417516738.SGD","BK0174","09067","LU0880133367.SGD","BK4099","BK4574","LU0348766576.USD","LU2488822045.USD","09926","LU0540923850.HKD","NIOG","LU1064130708.USD","BK0012","BK4555","BK4509","KURE","LU1794554557.SGD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144350622","title":"Hong Kong Stocks Open: Hang Seng Index Turns Lower After Flat Start; Pharma Shares Defy Trend as AKESO Surges Nearly 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144350622","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144350622?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:04","pubTimestamp":1790647446,"startTime":"0","endTime":"0","summary":"On September 29, Hong Kong's three major indices opened mixed before collectively turning lower.The Hang Seng Index opened up 0.02% at 24,648.64 points, and was last down 0.59% at 24,496.54 points....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02837","09067","MCHmain","BK1574","KURE","LU0417516902.SGD","LU0417516738.SGD","07300","HSI","LU0348827113.USD","02828","LU2778985437.USD","07200","LU2476274308.USD","HSTECH","LU0561508036.HKD","03088","LU0417516571.SGD","02833","07552","LU1794554557.SGD","03423","03417","BK1161","HSCEI","02802","07588","82800","LU0348766576.USD","LU0540923850.HKD","83115","LU0348767384.USD","LU0348784397.USD","IE00B5MMRT66.SGD","513600","09926","IE00B543WZ88.USD","LU0348825331.USD","LU2476274720.SGD","82828","03032","02800","03419","HHImain","LU0348783233.USD","IE00BPRC5H50.USD","07226","LU1961090484.USD","03067","03033","07288","03037","09088","HTImain","09115","03115","LU2399975544.HKD","03416","LU1720050803.USD","HSImain","LU2488822045.USD","LU0634319403.HKD","07500","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181831156","title":"Estimating the Value of PL-5: How Much Is This Wound Infection Candidate Worth for HK-Listed Aspirant Prolytix?","url":"https://stock-news.laohu8.com/highlight/detail?id=1181831156","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181831156?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:41","pubTimestamp":1790646095,"startTime":"0","endTime":"0","summary":"Recently, Prolytix filed for a Hong Kong listing for the second time. The company's core innovative drug, pramlintide sodium spray (PL-5), has received marketing approval from the National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1574","09939","IPOS","159938","BK4585","BK1515","BK1161","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130832239","title":"Prairie Pharmaceutical's Second Attempt at HKEX Listing: Cash Crunch, Billion-Yuan Redemption Liability Looming, Core Product Commercialization Faces Multiple Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=1130832239","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130832239?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:41","pubTimestamp":1790646076,"startTime":"0","endTime":"0","summary":"Recently, Prairie Pharmaceutical submitted its second main board listing application to the Hong Kong Stock Exchange, seeking to list under Chapter 18A rules. Just three months earlier, the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1161","09939","BK1574","BK1515","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131412257","title":"Akeso Biotech Jumps Over 8% at Open as AstraZeneca Makes US$2 Billion Strategic Investment in Summit, Ivonescimab Gains Backing from Top Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1131412257","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131412257?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:28","pubTimestamp":1790645294,"startTime":"0","endTime":"0","summary":"Akeso Biotech (09926) opened more than 8% higher, reaching 8.37% at HK$99.7 as of press time, with a turnover of HK$56.2558 million.On the news front, Akeso Biotech's overseas partner Summit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU0348766576.USD","LU0417516571.SGD","09926","BK4585","IE00BPRC5H50.USD","LU0348735423.USD","LU2399975544.HKD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","BK1161","LU0417516902.SGD","BK4588","BK1574","LU1961090484.USD","LU0348783233.USD","LU1794554557.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348825331.USD","KCAI","LU2476274308.USD","LU0540923850.HKD","LU0348767384.USD","LU0348827113.USD","LU0561508036.HKD","LU2488822045.USD","LU2778985437.USD","VXUS","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179659197","title":"Eli Lilly Has Already Spent Over $20 Billion This Year! CEO Says It Will Target Pharma \"White Spaces\" and Continue Pursuing Larger Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=1179659197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179659197?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:05","pubTimestamp":1790643950,"startTime":"0","endTime":"0","summary":"Eli Lilly & Co (NYSE: LLY) Chief Executive Dave Ricks said investors can expect the company to pursue larger deals, similar to its $7.8 billion acquisition of Centessa Pharmaceuticals Plc, as it...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK4588","BK1574","KCE","CALF","BK4585","MYLD","BK1191","XMMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136239524","title":"AstraZeneca's $2 Billion Stake in Summit Signals Confidence in Akeso's Ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1136239524","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136239524?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:22","pubTimestamp":1790641354,"startTime":"0","endTime":"0","summary":"AstraZeneca has made a $2 billion strategic investment in Summit Therapeutics, pushing ivonescimab onto the center stage of global immuno-oncology competition. This deal not only serves as a major...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","LU2488822045.USD","LU0348827113.USD","LU0561508036.HKD","LU2476274308.USD","LU0417516738.SGD","LU2778985437.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD","09926","LU1720050803.USD","LU0348784397.USD","BK1161","KURE","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0540923850.HKD","LU0348766576.USD","LU1794554557.SGD","BK1574","IE00B543WZ88.USD","LU0348825331.USD","LU0348735423.USD","LU2476274720.SGD","LU2399975544.HKD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146102396","title":"CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B","url":"https://stock-news.laohu8.com/highlight/detail?id=1146102396","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146102396?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:10","pubTimestamp":1790640613,"startTime":"0","endTime":"0","summary":"According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","PSYK","BMED","IBBJ","IBBQ","BK1161","02171","BK1587","BK1574","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671707265","title":"CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2671707265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671707265?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640058,"startTime":"0","endTime":"0","summary":"CARsgen says first patient dosed in China Phase I registrational trial of CT1190B CAR-T for R/R LBCLCARsgen dosed the first patient in China in a registrational Phase I trial of CT1190B for relapsed o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4XW7vr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265701","title":"Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671265701?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640030,"startTime":"0","endTime":"0","summary":"Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. plaque psoriasis studyAscletis reported positive results from a 28-day U.S. proof-of-concept trial of ASC50 in plaque psoriasis.Results were pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4TYPnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108218509","title":"Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1108218509","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108218509?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640027,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial of ASC50 in patients with mild to moderate plaque...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01672","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671657252","title":"Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671657252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671657252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA8SGRHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}